This segment focuses on the research, development, and commercialization of innovative treatments for plaque psoriasis and atopic dermatitis. The primary focus is on ARQ-151 (ZORYVE®), a topical roflumilast cream, which has completed Phase III clinical trials and is FDA-approved. Research and development activities include ongoing clinical trials to evaluate long-term efficacy and safety, as well as exploring new formulations and indications. The company utilizes advanced topical drug delivery technologies to enhance skin penetration and efficacy. This segment addresses the significant unmet needs of patients suffering from chronic inflammatory skin conditions, aiming to improve their quality of life through effective and convenient treatments. Market positioning is strong due to the FDA approval of ZORYVE®, providing a competitive advantage in the dermatology market. Future opportunities include expanding the label for ZORYVE® and developing combination therapies. Regulatory aspects involve ongoing post-market surveillance and adherence to FDA guidelines. Partnerships with Kowa Pharmaceuticals America, Inc. for co-promotion in the U.S. and Sato for licensing in Japan are key to market access and commercial success.

This segment is dedicated to developing treatments for seborrheic dermatitis and scalp psoriasis, leveraging the company's expertise in topical formulations. The primary focus is on ARQ-154, a topical foam formulation of roflumilast. Research and development activities include Phase 2 proof-of-concept clinical trials to evaluate the efficacy and safety of ARQ-154. The company utilizes advanced formulation technologies to optimize drug delivery to the scalp and affected areas. This segment addresses the needs of patients suffering from these common and often challenging conditions, aiming to provide effective and convenient treatment options. Market positioning is based on the potential for ARQ-154 to offer a new treatment option for these conditions. Future opportunities include expanding the clinical program and seeking regulatory approval. Regulatory aspects involve clinical trial execution and submission of data to regulatory agencies. The company is actively seeking partnerships to accelerate the development and commercialization of ARQ-154.

This segment focuses on the development of treatments for hand eczema and vitiligo, utilizing a targeted approach with ARQ-252, a selective topical Janus kinase type 1 (JAK1) inhibitor. Research and development activities include preclinical studies and clinical trials to evaluate the efficacy and safety of ARQ-252. The company is employing advanced drug development techniques to optimize the formulation and delivery of ARQ-252. This segment addresses the unmet needs of patients suffering from these debilitating conditions, aiming to provide effective and targeted therapies. Market positioning is based on the potential of ARQ-252 to offer a new treatment option for these conditions. Future opportunities include expanding the clinical program and seeking regulatory approval. Regulatory aspects involve clinical trial execution and submission of data to regulatory agencies. The company is actively seeking partnerships to accelerate the development and commercialization of ARQ-252.

This segment is dedicated to developing a topical formulation of ARQ-252, designed to reach deeper into the skin to treat alopecia areata. Research and development activities include formulation development and preclinical studies to optimize drug delivery and efficacy. The company is leveraging its expertise in topical drug development to create a formulation that can effectively target the hair follicles. This segment addresses the needs of patients suffering from alopecia areata, aiming to provide a new treatment option for this condition. Market positioning is based on the potential of the ARQ-252 formulation to offer a new treatment option for alopecia areata. Future opportunities include expanding the clinical program and seeking regulatory approval. Regulatory aspects involve clinical trial execution and submission of data to regulatory agencies. The company is actively seeking partnerships to accelerate the development and commercialization of this formulation.